The role of idarubicin in adult acute lymphoblastic leukaemia: From drug resistance studies to clinical application

Leukemia and Lymphoma

Volumn 26, Issue SUPPL. 1, 1997, Pages 89-97

  Bassan, R ^a   Chiodini, B ^a   Lerede, T ^a   Torri, V ^b   Borleri, G ^a   Rambaldi, A ^a   Barbui, T ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Adult ALL; Drug resistance; Idarubicin

Indexed keywords

ANTHRACYCLINE; BCR ABL PROTEIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; IDARUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CONFERENCE PAPER; DRUG TRANSPORT; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031462450     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058605     Document Type: Conference Paper

References (26)

1. Henderson, E. S. (1983). Acute lymphocytic leukemia. In: Leukemia, (eds.) F. W. Gunz and E. S. Henderson, pp. 575-625. (Grune & Stratton Inc., New York.)
2. Hickman, J. A. (1996). Apoptosis and chemotherapy resistance. Eur J Cancer, 32A, 921-926.
3. Weathley, K. (1995). Meta-analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukaemia (Abstract). Blood, (Suppl 1), 86, 434a.
4. Bassan, R., Lerede, T., Rambaldi, A., Buelli, M., Viero, P. and Barbui, T. (1995). The use of anthracyclines in adult acute lymphoblastic leukemia. Haematologica, 80, 280-291.
5. Beck, W. T., Mueller, T. J. and Tanzer, L. R. (1979). Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res, 39, 2070-2076.
6. Speth, P. A. J., Linssen, P. C. M., Boezeman, J. B. M., Wessels, J. M. C. and Haanen, C. (1987). Leukemic cells and plasma daunomycin concentrations after bolus injections and 72h infusion. Cancer Chemother Pharmacol, 20, 311-315.
7. Speth, P. A. J., Van de Loo, F. A. J., Linssen, P. C. M., Wessels, J. M. C. and Haanen, C. (1986). Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demeythoxydaunomycin. Clin Pharmacol Ther, 40, 643-649.
8. List, A. F., Spier, C, Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M. and Dalton, W. (1993). Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol, 11, 1652-1660.
9. - cases. Blood, 86, 2329-2342.
10. Kokenberg, E., Sonneveld, P., Delwel, R., Sizoo, W., Hagenbeek, A. and Löwenberg, B. (1988). In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia, 2, 511-517.
11. Pieters, R., Loonen, A. H., Huismans, D. R., Broekema, G. J., Dirven, M. W. J., Heyenbrok, M. W., Hählen, K. and Veerman, A. J. P. (1990). In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood, 76, 2327-2336.
12. Bassan, R., Battista, R., Rohatiner, A. Z. S., Love, S., Carter, M., Buelli, M., Viero, P., D'Emilio, A., MacCallum, P., Amess, J., Dini, E., Barbui, T. and Lister, T. A. (1992). Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period. Leukemia, 6 (suppl 2), 186-190.
13. Bassan, R., Battista, R., Corneo, G., Rossi, G., Lambertenghi-Deliliers, G., Viero, P., Rambaldi, A., D'Emilio, A., Neonata, M. G., Pogliani, E., Oriani, A., Izzi, T., Dini, E. and Barbui, T. (1993). Idarubicin in the initial treatment of adults with acute lymphoblastic leukemia: the effect of drug schedule on outcome. Leuk Lymphoma, 11, 105-110.
14. Todeschini, G., Meneghini, V., Pizzolo, G., Cassiba, V., Ambrosetti, A., Veneri, D., Nadali, G., Zanotti, R., Tecchio, C. and Perona, G. (1994). Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia, 8, 376-381.
15. Bassan, R. and Barbui, T. (1995). Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica, 80, 82-90.
16. Goasguen, J. E., Dossot, J-M., Fardel, O., Le Mee, F., Le Gall, E., Leblay, R., LePrise, P. Y., Chaperon, J. and Fauchet, R. (1993). Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood, 81, 2394-2398.
17. Sauerbrey, A., Zintl, F. and Volm, M. (1994). P-glycoprotein and glutathione S-transferase π in childhood acute lymphoblastic leukaemia. Br J Cancer, 70, 1144-1149.
18. Berman, E. and McBride, M. (1992). Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood, 79, 3267-3273.
19. Ross, D., Tong, Y. and Comblatt, B. (1993). Idarubicin (IDA) is less vulnerable to transport-mediated multidrug resistance (MDR) than its metabolite idarubicinol (IDAol) or daunorubicin (DNR) (Abstract). Blood, 82, 257a.
20. Zanette, L., Zucchetti, M., Freshi, A., Erranti, D., Tirelli, U. and D'Incalci, M. (1990). Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol, 25, 445-448.
21. Borst, P. and Schinkel, A. H. (1996). What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer, 32A, 985-990.
22. Lehnert, M. (1996). Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer, 32A, 912-920.
23. Weiss, M., Telford, P., Kempin, S., Kritz, A., Sogoloff, H., Gee, T., Berman, E., Scheinberg, D., Little, C., Gaynor, J., Belanger, C., Bertino, J., Andreeff, M., McKenzie, S. and Clarkson, B. (1993). Severe toxicity limits intensification of induction therapy for acute lymphoblastic leukemia. Leukemia. 7, 832-837
24. Petti, M. C. and Mandelli, F. (1989). Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA. Seminars in Oncology, 16 (Suppl 2), 10-15.
25. Ellison, R. R., Mick, R., Cuttner, J., Schiffer, C. A., Silver, R. T., Henderson, H. S., Woliver, T., Royston, I., Davey, F. R., Glicksman, A. S., Bloomfield, C. D. and Holland, J. F. (1991). The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. J Clin Oncol, 9, 2002-2015.
26. Consoli, U., Priebe, W., Ling, Y.-H., Mahadevia, R., Griffin, M., Zhao, S., Perez-Soler. R. and Andreef, M. (1996). The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood, 88, 633-644.